Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Goodwill & Intangibles (2024 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Goodwill & Intangibles for 2 consecutive years, with $14.5 million as the latest value for Q4 2025.

  • Quarterly Goodwill & Intangibles rose 96.07% to $14.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Dec 2025, up 96.07% year-over-year, with the annual reading at $14.5 million for FY2025, 96.07% up from the prior year.
  • Goodwill & Intangibles hit $14.5 million in Q4 2025 for ARS Pharmaceuticals, up from $125000.0 in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $14.5 million in Q4 2025 to a low of $125000.0 in Q3 2025.